[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AponiaAnalytics Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1816152863069925376.png) aponia_analytics [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) on x 4966 followers
Created: 2025-07-20 15:31:52 UTC

🦉 LEADER trial: liraglutide reduced major cardiovascular events in type X diabetes patients. Heart protection—now a confirmed clinical endpoint for several GLP-1 receptor agonists.

#GLP1 #diabetes $NVO $LLY $AZN $SNY $GSK $PFE $RHHBY $ZLDPF


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1946956227721765198/c:line.svg)

**Related Topics**
[manat](/topic/manat)
[$zldpf](/topic/$zldpf)
[$rhhby](/topic/$rhhby)
[$gsk](/topic/$gsk)
[$sny](/topic/$sny)
[$lly](/topic/$lly)
[events](/topic/events)
[$nvo](/topic/$nvo)

[Post Link](https://x.com/AponiaAnalytics/status/1946956227721765198)